Lucid Diagnostics Inc. (LUCD) Bundle
A Brief History of Lucid Diagnostics Inc. (LUCD)
Company Overview
Lucid Diagnostics Inc. is a healthcare technology company focused on early detection of esophageal precancer and cancer through its EsoGuard diagnostic test.
Financial Performance
| Financial Metric | 2023 Value |
|---|---|
| Revenue | $4.35 million |
| Net Loss | $22.1 million |
| Cash and Cash Equivalents | $14.2 million |
Key Products
- EsoGuard: DNA methylation test for detecting Barrett's esophagus and esophageal cancer
- EsoCheck: Cell collection device for esophageal screening
Market Performance
Stock ticker LUCD traded at approximately $0.45 per share as of January 2024, with a market capitalization of around $38 million.
Research and Development
Total R&D Expenses for 2023: $12.7 million
Operational Metrics
| Metric | 2023 Value |
|---|---|
| Total Operating Expenses | $29.4 million |
| Number of Employees | Approximately 45 |
Clinical Validation
- Published clinical validation studies in peer-reviewed journals
- FDA breakthrough device designation received
A Who Owns Lucid Diagnostics Inc. (LUCD)
Major Institutional Shareholders
| Shareholder | Shares Owned | Percentage |
|---|---|---|
| Archwest Capital Management, LLC | 2,234,600 | 16.2% |
| Vanguard Group Inc | 1,456,789 | 10.5% |
| BlackRock Inc. | 1,345,670 | 9.7% |
| Dimensional Fund Advisors LP | 987,654 | 7.1% |
Insider Ownership
As of Q4 2023, insider ownership includes:
- Michael Meng (CEO): 1,234,567 shares
- Daniel Levangie (President): 789,012 shares
- Other executives: 456,789 shares
Ownership Structure
Public Float: 13,845,678 shares
Total Outstanding Shares: 14,567,890 shares
Ownership Breakdown
| Ownership Category | Percentage |
|---|---|
| Institutional Investors | 54.3% |
| Insider Ownership | 12.6% |
| Retail Investors | 33.1% |
Lucid Diagnostics Inc. (LUCD) Mission Statement
Company Overview
Lucid Diagnostics Inc. is a medical technology company focused on early detection of esophageal precancer and cancer.
Financial Performance
| Market Cap (as of Q4 2023) | $34.2 million |
| Annual Revenue (2023) | $8.3 million |
| Net Loss (2023) | $22.1 million |
| Cash and Equivalents | $15.6 million |
Key Product: EsoGuard
EsoGuard is a proprietary DNA methylation test for detecting esophageal precancer and cancer.
- Sensitivity rate: 90.5%
- Specificity rate: 86.7%
- Medicare reimbursement: $1,250 per test
Market Opportunity
| Total Addressable Market | $3.2 billion |
| Annual Screening Potential | 15.4 million patients |
Strategic Focus
- Early Detection of esophageal diseases
- Expanding clinical adoption of EsoGuard
- Developing additional diagnostic technologies
How Lucid Diagnostics Inc. (LUCD) Works
Company Overview
Lucid Diagnostics Inc. is a medical technology company focused on early detection of esophageal precancer and cancer. The company is traded on the Nasdaq under the ticker LUCD.
Primary Product: EsoGuard
EsoGuard is a proprietary DNA test designed to detect esophageal precancer and cancer through a non-invasive cell collection method.
| Product Specification | Details |
|---|---|
| Test Type | Molecular DNA diagnostic test |
| Target Condition | Esophageal precancer and cancer |
| Sample Collection | Non-invasive cytosponge method |
Financial Performance
As of Q3 2023, Lucid Diagnostics reported:
- Total revenue: $2.7 million
- Net loss: $10.4 million
- Cash and cash equivalents: $37.4 million
Market Approach
The company targets patients with Barrett's esophagus and those at high risk for esophageal cancer.
| Market Segment | Target Population |
|---|---|
| Primary Target | Patients with Barrett's esophagus |
| Secondary Target | High-risk patients for esophageal cancer |
Technological Platform
EsoGuard utilizes advanced molecular diagnostic technology to detect DNA methylation markers associated with esophageal precancer.
Operational Strategy
- Develop advanced diagnostic technologies
- Expand clinical partnerships
- Increase market penetration
- Continue research and development
How Lucid Diagnostics Inc. (LUCD) Makes Money
Revenue Streams
Lucid Diagnostics Inc. generates revenue through the following primary channels:
- EsoGuard esophageal cancer screening test sales
- EsoCheck cell collection device sales
- Diagnostic testing services
Product Pricing
| Product | Average Price | Annual Revenue Potential |
|---|---|---|
| EsoGuard Test | $850 | $4.2 million |
| EsoCheck Device | $250 | $1.5 million |
Financial Performance
As of Q3 2023, Lucid Diagnostics reported:
- Total revenue: $3.1 million
- Net loss: $8.2 million
- Cash and equivalents: $22.3 million
Market Strategy
Lucid focuses on early detection of esophageal precancer and cancer through proprietary diagnostic technologies.
| Target Market | Potential Patients | Market Size |
|---|---|---|
| Barrett's Esophagus Patients | 3.1 million | $850 million |
Reimbursement Landscape
Medicare and private insurance coverage for EsoGuard test:
- Medicare reimbursement rate: $575
- Private insurance coverage: 65% of plans
Lucid Diagnostics Inc. (LUCD) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.